| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(6 years from now) | |
| US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(7 years from now) | |
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(15 years from now) | |
Mounjaro is owned by Eli Lilly And Co.
Mounjaro contains Tirzepatide.
Mounjaro has a total of 4 drug patents out of which 0 drug patents have expired.
Mounjaro was authorised for market use on 28 July, 2023.
Mounjaro is available in solution;subcutaneous dosage forms.
Mounjaro can be used as mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Drug patent challenges can be filed against Mounjaro from 13 May, 2026.
The generics of Mounjaro are possible to be released after 14 June, 2039.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using
TIRZEPATIDE ingredient
NCE-1 date:
13 May, 2026
Market Authorisation Date:
28 July, 2023Treatment:
Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitusDosage:
SOLUTION;SUBCUTANEOUS
More Information on Dosage
MOUNJARO family patents
